Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug;7(16):367.
doi: 10.21037/atm.2019.06.01.

Postoperative albumin-bilirubin grade and albumin-bilirubin change predict the outcomes of hepatocellular carcinoma after hepatectomy

Linsen Ye  1 , Rongpu Liang  1 , Jiebin Zhang  1 , Chaojin Chen  2 , Xiaolong Chen  1 , Yi Zhang  1 , Guoying Wang  1 , Yang Yang  1 , Guihua Chen  3   4
Affiliations

Postoperative albumin-bilirubin grade and albumin-bilirubin change predict the outcomes of hepatocellular carcinoma after hepatectomy

Linsen Ye et al. Ann Transl Med. 2019 Aug.

Abstract

Background: The albumin-bilirubin (ALBI) grade is an index that could objectively evaluate liver function. The purpose of this study was to evaluate the prognostic value of postoperative ALBI (post-ALBI) grade and ALBI changes (△ALBI) after hepatectomy in patients with hepatocellular carcinoma (HCC).

Methods: The clinical and pathological data of 300 patients with HCC who underwent hepatectomy in the Third Affiliated Hospital of Sun Yat-Sen University from January 19, 2009 to December 25, 2014, were analyzed retrospectively. According to the test data, the patients were divided into post-ALBI grade I, post-ALBI grade II, and post-ALBI grade III groups. According to the receiver operating characteristic curves (ROC), the patients were divided into △ALBI (△ALBI >0.71) high and low groups (△ALBI ≤0.71). Baseline clinical data, recurrence-free survival (RFS) and overall survival (OS) rates were compared between the groups.

Results: The 1-, 3-, and 5-year RFS rates and OS rates of patients with post-ALBI grade III were significantly reduced in comparison to those with post-ALBI grade II (P<0.001 both). Between the △ALBI groups, patients with low △ALBI level had significantly reduced 1-, 3-, and 5-year RFS rates and OS rates compared to those with a high △ALBI level (P<0.001 both). Multivariate analyses indicated that higher post-ABLI grade and △ALBI level were significantly independent predictors of an inferior OS and RFS (P<0.05).

Conclusions: This study confirmed for the first time that post-ALBI grade and △ALBI could predict the prognosis of patients with HCC after hepatectomy.

Keywords: Carcinoma; albumin-bilirubin (ALBI); hepatectomy; hepatocellular; prognosis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Receiver operating characteristics curve for △ALBI to predict the survival of patients with hepatocellular carcinoma after hepatectomy. △ALBI, albumin-bilirubin change.
Figure 2
Figure 2
Kaplan-Meier survival analysis of post-ALBI grade in patients with hepatocellular carcinoma after hepatectomy. (A) Recurrence-free survival according to post-ALBI grade; (B) overall survival according to post-ALBI grade. post-ALBI, postoperative albumin-bilirubin.
Figure 3
Figure 3
Kaplan-Meier survival analysis of △ALBI in patients with hepatocellular carcinoma after hepatectomy. (A) Recurrence-free survival according to △ALBI; (B) overall survival according to △ALBI. △ALBI, albumin-bilirubin change.
See this image and copyright information in PMC

References

    1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27. 10.1056/NEJMra1001683 - DOI - PubMed
    1. Zhong JH, Ma L, Li LQ. Postoperative therapy options for hepatocellular carcinoma. Scand J Gastroenterol 2014;49:649-61. 10.3109/00365521.2014.905626 - DOI - PubMed
    1. Poon RT, Ng IO, Fan ST, et al. Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. J Clin Oncol 2001;19:3037-44. 10.1200/JCO.2001.19.12.3037 - DOI - PubMed
    1. Zhong JH, Li H, Li LQ, et al. Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. Eur J Surg Oncol 2012;38:286-95. 10.1016/j.ejso.2012.01.006 - DOI - PubMed
    1. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200-7. 10.1016/S0168-8278(02)00360-4 - DOI - PubMed